Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|ASP7517||ASP 7517|ASP-7517||ASP7517 comprises artificial adjuvant vector cells engineered to express CD1d, which are loaded with the Wilms' tumor 1 (WT1) antigen and the CD1d ligand alpha-galactosylceramide on the cell surface, which may result in the activation of antitumor immune response against tumor cells expressing WT1 (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04837196||Phase Ib/II||ASP7517 + Pembrolizumab ASP7517||Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen||Recruiting||USA||0|